{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:53Z","timestamp":1790662133072,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2018,5,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Fabry disease is an X-linked lysosomal storage disorder caused by\ndeficient activity of \u03b1 -galactosidase A which leads to progressive intracellular accumulation\nof globotriaosylceramide in tissues and organs including heart, kidney, vascular endothelium,\nthe nervous system, the eyes and the skin. Cardiac involvement is common, leads to fatal\ncomplications and is mainly responsible for reduced life expectancy in Fabry disease. The exact\nstaging of disease progression and timely initiation of treatment is essential in Fabry disease.\nTherefore, it is essential to use the possibilities of specific biomarkers for early detection\nof organ involvement or early diagnosis.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> By the use of Pubmed all relevant papers for biomarkers in Fabry disease were\nscreened. The quality of retrieved papers was appraised using standard tools. Finally, 70 peer\nreviewed paper were included.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> In the past biomarkers for Fabry disease biomarkers did not have clinical relevance.\nNowadays, a lot of research is focusing on identification of new biomarkers and their clinical\nrelevance. Only two biomarkers reached clinical applicability. Lyso-GB3 for identification of\natypical FD variants and hsTNT for identification of cardiac involvement, which should indicate\nfurther diagnostics. Treatment response to ERT can be monitored by lyso-GB3 but data\nfor long-time outcome are missing. A lot of GB3-related analogs are identified in urine and\nplasma, some of which might play an important role for managing Fabry disease in future.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In conclusion, we suggest to measure lyso-GB3 and hsTNT at least once a year.\nThe routine measurement of these two biomarkers will help now for the staging of every individual\npatient and in addition, will help for a better general understanding of Fabry disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867324666170616102112","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T20:14:44Z","timestamp":1497644084000},"page":"1530-1537","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Biomarkers for Diagnosing and Staging of Fabry Disease"],"prefix":"10.2174","volume":"25","author":[{"given":"Johannes","family":"Kramer","sequence":"first","affiliation":[{"name":"Department of Medicine, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy, University of Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy, University of Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/153347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/153347\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/153347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T09:58:54Z","timestamp":1608890334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/153347\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":0,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,5,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666170616102112","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}